Lacosamide Hikma

Lacosamide, the active ingredient in Lacosamide Hikma, is an anti‑epileptic presented as an injection for intravenous use. It is used as adjunctive therapy for partial‑onset seizures in patients with epilepsy. GNH USA supplies Lacosamide Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Lacosamide is an anti‑epileptic drug that acts on neuronal sodium channels to control seizure activity.

Partial‑onset seizures: reduces seizure frequency when added to existing therapy. Adjunctive therapy in refractory epilepsy: provides additional seizure control for patients not responding to other medications. Epilepsy (generalized): used as part of a broader treatment regimen to manage overall seizure burden.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild gastrointestinal upset. - Headache: occasional throbbing pain. - Fatigue: feeling unusually tired. - Peripheral edema: swelling of the extremities. - Vision changes: blurred or double vision.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, especially PR‑interval prolongation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Respiratory depression: difficulty breathing. - Anaphylaxis: severe allergic reaction. - Hepatotoxicity: liver enzyme elevation. - Suicidal ideation: thoughts of self‑harm.

When using Lacosamide injection, clinicians should consider several safety measures.

Cardiac monitoring: observe ECG for PR‑interval changes. Renal impairment: adjust therapy in patients with reduced kidney function. Hepatic dysfunction: use caution in liver disease. Concomitant anti‑seizure drugs: assess for additive CNS depression. Pregnancy and lactation: evaluate risk‑benefit before prescribing. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Carbamazepine: may reduce lacosamide plasma levels. - Phenytoin: may decrease efficacy of lacosamide. - Rifampin: can increase clearance of lacosamide.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): may raise lacosamide concentrations. - CYP2C19 inducers (e.g., omeprazole): may lower lacosamide levels. - Other sodium‑channel blockers: monitor for additive CNS effects.